Drugs / GH55
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07446725 | Feb 2026 → Oct 2029 expected | — | Suzhou Genhouse Bio Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06310382 | Dec 2022 → May 2025 overdue | — | Suzhou Genhouse Bio Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GH55 | “GH55 Capsule is a novel, highly selective small molecule dual mechanism ERK1/2 inhibitor.” NCT07446725 ↗ |
| Action | Inhibit | “GH55 Capsule is a novel, highly selective small molecule dual mechanism ERK1/2 inhibitor.” NCT07446725 ↗ |
| Modality | Small molecule | “GH55 Capsule is a novel, highly selective small molecule dual mechanism ERK1/2 inhibitor.” NCT07446725 ↗ |
| Route | Oral | “oral administration of GH55” NCT06310382 ↗ |